Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Abortion Drugs

Abortion Drugs

81 results

Filter Results By

Filter Applied. Clear All
Reset All Filters
81 results
Abortion Drugs

Public Health Threat: Delaware DHSS Data Reveals Dramatic Increase in Risky Abortion Method

The most recent Delaware Health and Social Services data shows a dramatic increase in the use of potentially dangerous abortion drugs which multiple peer-reviewed studies have linked to higher rates of complications.

charlotte-lozier-institute Charlotte Lozier Institute
February 3, 2022
Please login to bookmarkClose
Abortion Drugs

Analysis: FDA Decision Ignores Data on Complications, Puts Women at Risk

As a dangerous drug, mifepristone has been subject to regulations put in place by the Food and Drug Administration (FDA) in 2000.[1] Under these regulations, called a Risk Evaluation and Mitigation Strategy (REMS), mifepristone may only be dispensed in person by certain qualified medical providers.

Abortion Drugs

Chemical Abortion: FDA Ignores ‘Inconvenient’ Science and Data Confirming Public Health Threat

The U.S. Food and Drug Administration (FDA) today announced plans to irresponsibly erode longstanding patient safeguards on the abortion pill, despite major U.S. and international research confirming that chemical abortion has led to a surge in emergency room visits and higher rates of complications.

Abortion Drugs

Overlooked Dangers of Mifepristone, the FDA’s Reduced REMS, and Self-Managed Abortion Policies: Unwanted Abortions, Unnecessary Abortions, Unsafe Abortions

The failure of abortion providers to support and undertake prospective longitudinal studies of a nationally representative sample of women contributes to our belief that the ideological biases of abortion providers have led to a combination of disinterest, willful ignorance, or even a conspiracy to hide the widespread dangers of unwanted and contraindicated abortions.

Abortion Drugs

Public Health Threat: Connecticut DPH Data Shows More Women Using Risky Abortion Method

Half of all Connecticut abortions are performed with potentially dangerous drugs which multiple peer-reviewed studies have linked to higher rates of complications.

Abortion Drugs

Public Health Threat: Colorado DPHE Data Reveals Dramatic Increase in Risky Abortion Method

The most recent State of Colorado abortion data shows a dramatic increase in the use of potentially dangerous abortion drugs which multiple peer-reviewed studies have linked to higher rates of complications.

Abortion Drugs

Public Health Threat: Chemical Abortion Leads to Significantly Higher Rate of ER Visits

As the Food and Drug Administration (FDA) works toward a December 16 decision on chemical abortion safeguards, a groundbreaking new study from Charlotte Lozier Institute (CLI) shows that increased access to abortion pills creates a significant public health risk.

featured-image
Abortion Drugs

A Longitudinal Cohort Study of Emergency Room Utilization Following Mifepristone Chemical and Surgical Abortions, 1999–2015

Existing research on postabortion emergency room visits is sparse and limited by methods which underestimate the incidence of adverse events following abortion. Postabortion emergency room (ER) use since Food and Drug Administration approval of chemical abortion in 2000 can identify trends in the relative morbidity burden of chemical versus surgical procedures.

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image